Accipiter Capital Management LLC Has Increased Teva Pharm Adr (TEVA) Stake by $6.83 Million; Stock Price Declined

March 14, 2018 - By Maria Brooks

Gabe Hoffman increased its stake in Teva Pharm Adr (TEVA) by 198.89% based on its latest 2017Q3 regulatory filing with the SEC. Accipiter Capital Management Llc bought 402,040 shares as the company’s stock declined 15.11% while stock markets rallied. The hedge fund run by Gabe Hoffman held 604,185 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $10.63M, up from 202,145 at the end of the previous reported quarter. Accipiter Capital Management Llc who had been investing in Teva Pharm Adr for a number of months, seems to be bullish on the $18.88B market cap company. The stock decreased 3.91% or $0.755 during the last trading session, reaching $18.565. About 7.32M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since March 14, 2017 and is downtrending. It has underperformed by 58.40% the S&P500.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: which released: “It’s Time to Add Teva Pharmaceutical Industries Ltd (ADR) Stock to Your Watchlist” on February 16, 2018, also with their article: “Trade of the Day: Teva Pharmaceutical Industries Ltd (ADR) (TEVA)” published on January 31, 2018, published: “Teva Needs More Than Job Cuts” on December 14, 2017. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: and their article: “Teva Pharmaceutical Industries Ltd ADR (TEVA) Names Kare Schultz As CEO” published on September 11, 2017 as well as‘s news article titled: “Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Fell Today” with publication date: August 03, 2017.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma had 147 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Monday, February 12 by Credit Suisse. The firm has “Underperform” rating given on Friday, January 5 by Wells Fargo. The company was maintained on Friday, February 9 by Deutsche Bank. On Monday, November 6 the stock rating was maintained by Credit Suisse with “Underperform”. The stock has “Buy” rating by Mizuho on Thursday, February 15. RBC Capital Markets maintained the stock with “Sell” rating in Monday, October 30 report. The company was maintained on Wednesday, April 5 by Cowen & Co. The company was maintained on Friday, December 15 by RBC Capital Markets. Cantor Fitzgerald maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Thursday, August 3. Cantor Fitzgerald has “Hold” rating and $2700 target. Mizuho initiated Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Monday, December 7. Mizuho has “Buy” rating and $79 target.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.